Market Cap | 5.85M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -12.05M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -26.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -72.00% |
Dividend | N/A | Price/Book | 280.00 | EPS next 5Y | - | 52W High Chg | -93.00% |
Recommedations | - | Quick Ratio | 0.04 | Shares Outstanding | 5.48M | 52W Low Chg | 35.00% |
Insider Own | 36.85% | ROA | -157.50% | Shares Float | 3.51M | Beta | 0.13 |
Inst Own | 0.55% | ROE | -541.13% | Shares Shorted/Prior | 15.40K/11.87K | Price | 0.28 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 212,579 | Target Price | - |
Oper. Margin | - | Earnings Date | - | Volume | 88,871 | Change | -6.67% |
GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.